Mira Pharmaceuticals, Inc. (MIRA): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of MIRA were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No MIRA insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MIRA short interest
Low short interest. 0.7% of MIRA shares are sold short: about 1 share in 149. Over the last 12 reports the number of shares short went down 31%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 282,319 MIRA shares were sold short, 0.7% of the shares outstanding, down 19.3% from the report before. At the average daily volume of 196,532 shares, buying them all back would take about 1.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 282,319 | 0.67% | -19% | 196,532 | 1.4 |
| Oct 15, 2026 | 349,714 | 0.83% | -14% | 148,305 | 2.4 |
| Sep 30, 2026 | 408,844 | 0.97% | -9% | 168,671 | 2.4 |
| Sep 15, 2026 | 447,832 | 1.07% | +118% | 3.13M | 1.0 |
| Aug 31, 2026 | 205,296 | 0.49% | -3% | 49,531 | 4.1 |
| Aug 14, 2026 | 211,083 | 0.50% | +3% | 138,569 | 1.5 |
| Jul 31, 2026 | 205,408 | 0.49% | -20% | 69,525 | 3.0 |
| Jul 15, 2026 | 255,261 | 0.61% | +35% | 46,335 | 5.5 |
| Jun 30, 2026 | 189,322 | 0.45% | -31% | 91,930 | 2.1 |
| Jun 15, 2026 | 275,048 | 0.65% | -25% | 103,488 | 2.7 |
| May 29, 2026 | 368,301 | 0.88% | -10% | 161,594 | 2.3 |
| May 15, 2026 | 408,157 | 0.97% | -1% | 110,609 | 3.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
MIRA Pharmaceuticals company events
MIRA Pharmaceuticals filed 21 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Oct 28, 2026.
- Oct 28, 2026AnnouncementShared information with investors. Filing
- Oct 22, 2026AnnouncementShared information with investors. Filing
- Sep 17, 2026AnnouncementShared information with investors. Filing
- Sep 16, 2026VoteReported shareholder vote results. Filing
- Sep 1, 2026AnnouncementShared information with investors. Filing
- Aug 6, 2026AnnouncementShared information with investors. Filing
- Jul 31, 2026ListingMira Pharmaceuticals, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days ended July 24, 2026, the Company no longer meets the requirement to… Filing
- Jul 10, 2026AnnouncementShared information with investors. Filing
- Jul 6, 2026AnnouncementShared information with investors. Filing
- Jun 25, 2026AnnouncementShared information with investors. Filing
- Jun 17, 2026AnnouncementShared information with investors. Filing
- Jun 8, 2026LeadershipAlan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. Filing
- Jun 4, 2026AgreementMIRA Pharmaceuticals, Inc. entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC. Filing
- May 27, 2026AgreementMIRA Pharmaceuticals, Inc. entered into Amendment No. 1 to that certain Exclusive License Agreement, effective November 15, 2023, by and between the Company and MIRALOGX LLC. Pursuant to the Amendment, the parties expanded the Company’s exclusive licensed territory relating to Ketamir-2 from the… Filing
- May 13, 2026AnnouncementShared information with investors. Filing
- May 13, 2026AnnouncementMIRA Pharmaceuticals, Inc. announced the publication of a peer-reviewed manuscript relating to SKNY-1, the Company’s investigational oral drug candidate being evaluated for obesity and nicotine addiction, in the International Journal of Molecular Sciences . The manuscript, titled “SKNY-1, a THCV… Filing
- Mar 23, 2026AnnouncementMIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND submission for inflammatory pain. Filing
- Mar 3, 2026AnnouncementMIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced that it has… Filing
- Feb 2, 2026AnnouncementMIRA Pharmaceuticals, Inc. announced that it has initiated dosing in the final cohort of its Phase 1 multiple ascending dose (MAD) clinical trial evaluating Ketamir-2, the Company’s lead oral NMDA receptor antagonist. Filing
- Dec 22, 2025LeadershipThe Compensation Committee of the Board of Directors of MIRA Pharmaceuticals, Inc. approved certain short-term and long-term incentive awards for the Company’s Chief Executive Officer, Erez Aminov. Filing
- Dec 5, 2025AnnouncementMIRA Pharmaceuticals, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.0001 per share, issuable under the At The Market Offering Agreement with Rodman & Renshaw LLC, dated August 12, 2024, and amended on… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
MIRA Pharmaceuticals financials
Famous investors that hold MIRA
1 of the 50 well-known investors we track reported holding MIRA in their latest 13F filing. The largest position is Ken Griffin's, worth $189K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 223,626 | $189K | 0.0% | +1098% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Mira Pharmaceuticals, Inc. (MIRA) stock
Are MIRA insiders buying or selling?
No MIRA insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in MIRA?
As of Oct 30, 2026, 282,319 MIRA shares were sold short, 0.7% of the shares outstanding, down 19.3% from the report before. At the average daily volume of 196,532 shares, buying them all back would take about 1.4 trading days (days to cover). See the history.
Which famous investors hold MIRA?
1 of the 50 well-known investors we track reported MIRA in their latest 13F filing, including Ken Griffin. The largest position is worth $189K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.